Paxlovid (nirmatrelvir and ritonavir) Archives - CDR

Hy-Vee Pharmacy now offering test-to-treat COVID-19 services

July 20, 2022 by Chain Drug Review Hy-Vee, Paxlovid (nirmatrelvir and ritonavir) Leading Headlines, Pharmacy, Retail News

WEST DES MOINES, Iowa —Hy-Vee, Inc. announced this week that all Hy-Vee Pharmacy locations across its eight-state region now offer test-to-treat COVID-19 services using the COVID-19 antiviral, Paxlovid, to help treat mild-to-moderate cases of COVID-19 in certain patients who are at high risk for progression to severe COVID-19. Earlier this month, the FDA authorized state-licensed

FDA authorizes pharmacists to prescribe Paxlovid with certain limitations

July 6, 2022 by Chain Drug Review FDA, Paxlovid (nirmatrelvir and ritonavir) Leading Headlines, Pharmacy

WASHINGTON — The U.S. Food and Drug Administration on Wednesday revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. “The FDA recognizes the important role pharmacists have played and continue to play